Royalty Pharma Reports 16.5% Revenue Growth to $674.1 Million in Q2 2026

Royalty Pharma plc reported a significant increase in its financial performance for the second quarter of 2026, with total income and other revenues reaching $674.1 million, a 16.5% increase from $578.7 million in the same period last year. The growth was primarily driven by a 15.9% rise in income from financial royalty assets, which amounted to $638.0 million, compared to $550.4 million in the prior year. For the first half of 2026, total revenues were $1.3 billion, up 13.8% from $1.1 billion in the first half of 2025. However, net income attributable to Royalty Pharma plc decreased by 44.4% to $17.9 million for the second quarter, compared to $32.2 million in the same quarter of 2025, while net income for the first half rose to $312.6 million from $271.5 million.

The company experienced notable changes in its operating expenses, which increased by 46.7% to $541.0 million in the second quarter, largely due to a provision for changes in expected cash flows from financial royalty assets amounting to $268.2 million. This was a significant shift from a provision income of $203.9 million in the same quarter of the previous year. Additionally, research and development funding expenses decreased by 67.4% to $97.9 million, reflecting a reduction in upfront payments compared to the previous year. General and administrative expenses also saw a slight decrease of 9.9% to $161.9 million, attributed to the absence of management fees following the company's internalization in May 2025.

Strategically, Royalty Pharma has continued to expand its portfolio through acquisitions and funding agreements. In the first half of 2026, the company invested $876.7 million in royalties, milestones, and other contractual receipts. Recent acquisitions include a royalty interest in AstraZeneca’s cliramitug for up to $425 million and a funding agreement with Teva Pharmaceuticals for TEV-’408, which could total $500 million. The company also reported a strong performance from its existing portfolio, with notable increases in royalty receipts from products like Tremfya and Evrysdi.

Operationally, Royalty Pharma's cash collections from financial royalty assets increased to $1.7 billion in the first half of 2026, compared to $1.6 billion in the same period of 2025. The company reported a cash and cash equivalents balance of $812.0 million as of June 30, 2026, up from $618.7 million at the end of 2025. The company’s total assets increased to $19.8 billion, with financial royalty assets accounting for a significant portion. The company continues to maintain a strong liquidity position, supported by its operational cash flows and access to credit facilities.

Looking ahead, Royalty Pharma anticipates continued growth driven by its strategic investments and the performance of its existing royalty portfolio. The company remains focused on leveraging its financial strength to pursue additional acquisition opportunities while managing its operational costs effectively. However, it acknowledges potential risks related to market conditions and the performance of the underlying biopharmaceutical products that could impact future results.